ENX-105
ENX-105 is an investigational new drug being developed by Engrail Therapeutics for the treatment of post-traumatic stress disorder. It is currently in the preclinical stage, trailing behind a closely related Engrail compound, ENX-104, which is focused on depression and anhedonia.
The drug is described as a dopamine D2 and D3 receptor antagonist and serotonin 5-HT1A and 5-HT2A receptor agonist. Its antagonistic potencies are 0.08nM at the dopamine D2L receptor, 0.8nM at the dopamine D2S receptor, and 3.8nM at the dopamine D3 receptor, whereas its activational potencies are 5nM at the serotonin 5-HT2A receptor and 16nM at the serotonin 5-HT1A receptor.
ENX-105 does not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence is putatively non-hallucinogenic. The drug has shown anxiolytic-, antipsychotic-, anti-anhedonic-, and pro-cognitive-like effects in rodents. It has also been found to increase dopamine levels in the nucleus accumbens in rodents.
As with ENX-104, ENX-105 is a deuterated enantiomer of nemonapride.